ReviewCurrent genetics2003
Protective mechanisms against the antitumor agent bleomycin: lessons from Saccharomyces cerevisiae.
Review in Current genetics, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 64 citations in OpenAlex.
- Uncovering Bleomycin-Induced Genomic Alterations and Underlying Mechanisms in the YeastApplied and environmental microbiology · 2022Article
- Breast Cancer-Derived Microvesicles Are the Source of Functional Metabolic Enzymes as Potential Targets for Cancer Therapy.Biomedicines · 2021Article
- Rapid functional activation of a horizontally transferred eukaryotic gene in a bacterial genome in the absence of selection.Nucleic acids research · 2019Article
- Yeast Lacking the PP2A Phosphatase Regulatory Subunit Rts1 SensitizesFrontiers in genetics · 2019Article
- Pingyangmycin and Bleomycin Share the Same Cytotoxicity Pathway.Molecules (Basel, Switzerland) · 2016Article
- INO80 Chromatin Remodeler Facilitates Release of RNA Polymerase II from Chromatin for Ubiquitin-Mediated Proteasomal Degradation.Molecular cell · 2015Article
- Enhanced efficacy of bleomycin in bladder cancer cells by photochemical internalization.BioMed research international · 2014Article
- A multistep genomic screen identifies new genes required for repair of DNA double-strand breaks in Saccharomyces cerevisiae.BMC genomics · 2013Article
- Oxidative stress and replication-independent DNA breakage induced by arsenic in Saccharomyces cerevisiae.PLoS genetics · 2013Article
- A viable hypomorphic allele of the essential IMP3 gene reveals novel protein functions in Saccharomyces cerevisiae.PloS one · 2011Article
- The human carnitine transporter SLC22A16 mediates high affinity uptake of the anticancer polyamine analogue bleomycin-A5.The Journal of biological chemistry · 2010Article
- Does single-dose cell resistance to the radio-mimetic zeocin correlate with a zeocin-induced adaptive response in Chlamydomonas reinhardtii strains?Radiation and environmental biophysics · 2009Article
- Inhibition of DNA double-strand break repair by the Ku heterodimer in mrx mutants of Saccharomyces cerevisiae.DNA repair · 2009Article
- Differential requirements for RAD51 in Physcomitrella patens and Arabidopsis thaliana development and DNA damage repair.The Plant cell · 2007Article
- Mdt1 facilitates efficient repair of blocked DNA double-strand breaks and recombinational maintenance of telomeres.Molecular and cellular biology · 2007Article
- Murine candidate bleomycin induced pulmonary fibrosis susceptibility genes identified by gene expression and sequence analysis of linkage regions.Journal of medical genetics · 2005Article
- Characterization of a transport and detoxification pathway for the antitumour drug bleomycin in Saccharomyces cerevisiae.The Biochemical journal · 2004Article
- Isolation and characterization of Saccharomyces cerevisiae mutants with enhanced resistance to the anticancer drug bleomycin.Current genetics · 2004Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bleomycin is a small glycopeptide antibiotic used in combination therapy for the treatment of a few types of human cancer. The antitumor effect of bleomycin is most likely caused by its ability to bind to DNA and induce the formation of toxic DNA lesions via a free radical reactive (Fe.bleomycin) complex. However, the chemotherapeutic potential of bleomycin is limited, as it causes pulmonary fibrosis and tumor resistance at high doses. The chemical structure and modes of action of bleomycin have been extensively studied and these provide a foundation towards improving the therapeutic value of the drug. This review provides a first account of the current state of knowledge of the cellular processes that can allow the yeast Saccharomyces cerevisiae to evade the lethal effects of bleomycin. This model organism is likely to provide rapid clues in our understanding of bleomycin resistance in tumor cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.